

- enzyme replacement therapy on five patients with advanced late-onset glycogen storage disease type II : a 2-year follow-up study J Inherit Metab Dis 2012;35(2):301-10
4. Yamamoto T, Kobayashi Y, Murata M. Risk of pneumonia onset and discontinuation of oral intake following videofluorography in patients with Lewy body disease. Parkinsonism Relat Disord. 2010;16:503-506
 5. Murata M. ZONISAMIDE : A New drug for Parkinson's disease Drug of today 2010;46(4): 251-258
 6. 藤本健一, 村田美穂, 服部信孝, 近藤智善. 大規模患者調査で明らかになった日本における Parkinson 病薬物治療の実態. BRAIN and NERVE 2011; 63(3):255-265
 7. 山本敏之, 小林庸子, 村田美穂. 2次元動画解析ソフトによる嚥下造影検査の嚥下動態の評価 耳鼻と臨床 2010;56:S235-S239.
 8. 村田美穂. ハンチントン病 今日の精神疾患治療指針 樋口輝彦, 市川宏伸, 神庭重信, 朝日 隆, 中込和幸編 医学書院 東京 2012,404-407
 9. 岡本智子, 村田美穂. パーキンソン病 今日の精神疾患治療指針 樋口輝彦, 市川宏伸, 神庭重信, 朝日 隆, 中込和幸編 医学書院 東京 2012,pp400-404
 10. 村田美穂. パーキンソン病ガイドライン 2011 日本神経学会監修 「パーキンソン病治療ガイドライン」作成委員会 東京 2011
 11. 村田美穂. 性機能障害の原因とその対策 よくわかるパーキンソン病のすべて水野美邦, 近藤智善編 永井書店 東京 2011,pp112-115
 12. 村田美穂 リハビリスタッフに求められる 薬・栄養・運動の知識 内部障害のケアのために 上月正博編, 南江堂, 東京,2010,pp179-188.
 13. 村田美穂 パーキンソン病の内科的治療 今日の治療指針 2010 山口 徹, 北原光夫, 福井次矢編 医学書院 東京 2010,pp751-753.
 14. 古澤嘉彦, 村田美穂. パーキンソン病の薬物療法 : その他の薬の使い方, 特徴 Moders Physician 2012;32(2):193-196
 15. 村田美穂. パーキンソン病治療薬の課題と創薬への期待 ヒューマンサイエンス 2011;22(4):22-25
 16. 有馬邦正, 村田美穂, 佐藤典子. 先端認知症研究・医療施設の現在 Cognition and Dementia 2011;10(2):78-81
 17. 村田美穂. パーキンソン病の分子病態と治療 Rad Fan 2011;9(5):35-37
 18. 岡本智子, 村田美穂. 抗パーキンソン病薬の種類と使い方, 注意すべき副作用 内科 2011;107(5) 813-816
 19. 村田美穂. 進行期パーキンソン病における諸問題について Pharma Medica 2011;29(3) :175-179

研究分担者：後藤雄一

1. Shiomi K, Kiyono T, Okamura K, Uezumi M, Ogoto Y, Yasumoto S, Shimiz S6, Hashimoto N. CDK4 and Cyclin D1 Allow Human Myogenic Cells to Recapture Growth Property Without Compromising Differentiation Potential. *Gene Therapy* 18:857-866, 2011.
2. Miyake K, Hirasawa T, Soutome M, Itoh M, Ogoto Y, Endoh K, Takahashi K, Kudo S, Nakagawa T, Yokoi S, Taira T, Inazawa J, Kubota T. The protocadherins, PCDHB1 and PCDH7, are regulated by MeCP2 in neuronal cells and brain tissues: implication for pathogenesis of Rett syndrome. *BMC Neuroscience* 12:81, 2011
3. Waga C, Okamoto N, Ondo Y, Fukumura-Kato R, Ogoto Y, Kohsaka S, Uchino S. Novel variants of the SHANK3 gene in Japanese autistic patients with severe delayed speech development. *Psychiatr Genet* 21:208-11, 2011
4. Takeshita E, Saito Y, Nakagawa E, Komaki H, Sugai K, Sasaki M, Nezu A, Kitamura J, Itoh M, Sawano Y, Ogoto Y. Late-onset mental deterioration and fluctuating dystonia in a female patient with a truncating MECP2 mutation. *J Neurol Sci* 308:168-72, 2011

研究分担者：功刀浩

1. Sasayama D, Hori H, Teraishi T, Hattori K, Ota M, Matsuo J, Kawamoto Y, Kinoshita Y, Hashikura M, Amano N, Higuchi T, Kunugi H. More severe impairment of manual dexterity in bipolar disorder compared to unipolar major depression. *J Affect Disord*. 2012 Feb;136(3):1047-52. Epub 2011 Dec 12. PubMed PMID: 22169250.
2. Wakabayashi C, Numakawa T, Ninomiya M, Chiba S, Kunugi H. Behavioral and molecular evidence for psychotropic effects in L: -theanine. *Psychopharmacology (Berl)*. 2012 Feb;219(4):1099-109. Epub 2011 Aug 23. PubMed PMID: 21861094.
3. 功刀 浩：ドパミン受容体作動薬とうつ病。内分泌・糖尿病・代謝内科（印刷中）

研究分担者：川寄弘詔

1. Takata A, Kawasaki H, Iwayama Y, Yamada K, Gotoh L, Mitsuyasu H, Miura T, Kato T, Yoshikawa T, Kanba S: Nominal association between a polymorphism in DGKH and bipolar disorder detected in a meta-analysis of East Asian case-control samples. *Psychiatry Clin Neurosci*, 65(3):280-5, 2011
2. 尾崎紀夫, 坂本薫, 川寄弘詔, 加藤正木: 双極性障害における新たな治療選択肢-Lamotrigine の適応拡大を前に-. *臨床精神薬理*, 14(9): 1567-1575, 2011
3. 川寄弘詔: 院内における中立性を担保する第三者としての精神科医は, いかにドナー候補の同意能力および自発意識を評価するのか. *今日の移植*, 24(2): 141-146, 2011
4. 川寄弘詔, 光安博志: 双極 I 型障害と双極 II 型障害の違いを教えてください. うつ病の事典~うつ病と双極性障害がわかる本(樋口輝彦, 野村総一郎, 加藤忠史編著), 第 9 章 双極性障害のさまざまなタイプ, (神庭重信監修), pp84-86, こころの科学特別

号, 日本評論社, 東京, 2011

5. ○川寄弘詔: 院内における中立性を担保する第三者としての精神科医は, いかにかドナー候補の同意能力および自発意識を評価するのか. 移植, 46(1): 18-26, 2011
6. 春木繁一, 西村勝治, 阿部祥, 梅谷由美, 南里幸一郎, 桂川修一, 小林清香, 川岸直樹, 菅原寧彦, ○川寄弘詔: 討論: 特集 1 第 46 回日本移植学会ワークショップ “生体ドナーの意思決定にどのようにかわるか”. 今日の移植, 24(2): 161-164, 2011
7. ○川寄弘詔: 双極スペクトラムを巡って「第 107 回日本精神神経学会学術総会」より. 月刊 JMS 12 月号, pp42-45, 株式会社ジャパンメディカルソサエティ, 東京, 2011
8. ○川寄弘詔: STEP-BD. リンケージ解析 [連鎖解析]. 現代精神医学事典 (加藤敏, 神庭重信, 中谷陽二, 武田雅俊, 鹿島晴雄, 狩野力八郎, 市川宏伸編), p564, p1072, 弘文社, 東京, 2011

研究分担者: 米本直裕

1. Matsuoka Y, Nishi D, ○Yonemoto N, Hamazaki K, Hamazaki T, Hashimoto K.(2011) Potential role of brain-derived neurotrophic factor in omega-3 Fatty Acid supplementation to prevent posttraumatic distress after accidental injury: an open-label pilot study. *Psychother Psychosom*, 80(5), 310-2.
2. Furukawa TA, Akechi T, Shimodera S, Yamada M, Miki K, Watanabe N, Inagaki M, ○Yonemoto N.(2011) Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol. *Trials*. 11;12:116.
3. Nagai S, ○Yonemoto N, Rabesandratana N, Andrianarimanana D, Nakayama T, Mori R.(2011) Long-term effects of earlier initiated continuous Kangaroo Mother Care (KMC) for low-birth-weight (LBW) infants in Madagascar. *Acta Paediatr*. 100(12):e241-7.
4. 山田光彦, 稲垣正俊, ○米本直裕 (2011) 向精神薬と自殺予防, 臨床精神薬理 第 14 巻 12 号

研究分担者: 玉浦明美

研究分担者: 松岡豊

1. Komachi M, Kamibeppu K, Nishi D, ○Matsuoka Y: Secondary traumatic stress and associated factors among Japanese nurses working in hospitals. *Int J Nurs Practice* (in press)
2. Nishi D, Usuki M, Matsuoka Y: Peritraumatic distress in accident survivors: An indicator for posttraumatic stress, depressive and anxiety symptoms, and posttraumatic growth. In *Post Traumatic Stress Disorders*, InTech Open Access Publisher, Croatia, pp97-112, 2011 [ISBN 978-953-307-825-0]
3. Matsumura K, Noguchi H, Nishi D, ○Matsuoka Y: Effect of omega-3 fatty acids on the

- psychological assessment for secondary prevention of posttraumatic stress disorder: an open-label pilot study. *Global J Health Science* 4(1): 3-9, 2012
4. ○Matsuoka Y, Nishi D, Nakaya N, Sone T, Hamazaki K, Hamazaki T, Koido Y: Attenuating posttraumatic distress with omega-3 polyunsaturated fatty acids among disaster medical assistance team members after the Great East Japan Earthquake: The APOP randomized controlled trial. *BMC Psychiatry* 2011 Aug 16,11:132
 5. ○Matsuoka Y, Nishi D, Yonemoto N, Hamazaki K, Hamazaki T, Hashimoto K: Potential role of brain-derived neurotrophic factor in omega-3 fatty acid supplementation to prevent posttraumatic distress after accidental injury: An open-label pilot study. *Psychother Psychosom* 2011;80:310-312
 6. ○松岡豊, 西大輔: 魚油による PTSD 予防への挑戦. *精神神経学雑誌* 114:2012 (印刷中)
 7. 白杵正人, ○松岡豊, 西大輔: 集中治療室における急性ストレス障害 (ASD) と心的外傷後ストレス障害 (PTSD). *救急医療*, 2012 (印刷中)
 8. 白杵正人, 西大輔, ○松岡豊: 急性ストレス反応 (ASD)、心的外傷後ストレス障害 (PTSD) 患者への対応について教えてください. *救急・集中医療* 24(1-2), 2012 (印刷中)
 9. 西大輔, ○松岡豊: オメガ 3 系脂肪酸の可能性—うつ病および PTSD の治療と予防に向けて. *食品と開発* 47 (2): 25-27, 2012
 10. 西大輔, 白杵正人, 松村健太, ○松岡豊: 事故後の PTSD の予防に向けて. *精神科* 18(6):659-663, 2011
 11. ○松岡豊: 魚油による PTSD 予防への挑戦. *分子精神医学* 11(2): 154-156, 2011
 12. ○松岡豊, 浜崎景: うつ病と ω 3 系多価不飽和脂肪酸. *Depression Frontier* 9(1):35-43, 2011

研究分担者: 中川敦夫

1. ○中川敦夫:【うつ病の評価と治療】 うつ病治療のエビデンス・アップデート—薬物療法と認知行動療法を中心に—, *日本病院薬剤師会雑誌*, 47(2): 173-175, 2011
2. ○中川敦夫:【うつ病のお薬】 SSRI で自殺が増えたといわれますが、本当でしょうか?, *こころのりんしょう a・la・carte*, 30(1): 37, 2011
3. ○中川敦夫:【うつ病のお薬】 抗うつ薬と自殺関連リスク, *こころのりんしょう a・la・carte*, 30(1): 105-110, 2011
4. 加藤健徳, ○中川敦夫, 須藤清美, 井川恵子, 岩下覚, 【これからの精神科地域ケア—統合失調症を中心に—】 地域ケア時代の治療スキル 治療ガイドラインの活用, *臨床精神医学*, 40(5): 659-665, 2011
5. ○中川敦夫:【震災に伴う心のケア】 災害・災害関連事象に伴う不安への対応と対処—認知療法的な観点から—, *心と社会*, 42(3): 22-26, 2011
6. ○中川敦夫:【内科医のためのうつ病診療 一般内科医の対処と診療のすべて】 治療/実地医家が可能なうつ病診療の実際—うつ病の認知療法・認知行動療法の実際, *Medical*

Practice, 28(10) : 1846-1850, 2011

7. Ono Y, Furukawa TA, Shimizu E, Okamoto Y, Nakagawa A, Fujisawa D, Ishii T, Nakajima S., Current status of research on cognitive therapy/cognitive behavior therapy in Japan. *Psychiatry Clin Neurosci* 2011 Mar;65(2):121-129.
8. Fujisawa, D., Nakagawa, A., Kikuchi, T., Sado, M., Tajima, M., Hanaoka, M., Wright, J.H., Ono, Y., 2011. Reliability and validity of the Japanese version of the Cognitive Therapy Awareness Scale: a scale to measure competencies in cognitive therapy. *Psychiatry Clin Neurosci* 2011 Feb;65(1): 64-69.
9. Brian S. Everitt, Simon Wessley(著), 樋口輝彦, 山田光彦(監訳), 中川敦夫, 米本直裕(訳) ロンドン大学精神医学研究所に学ぶ 精神科臨床試験の実践, 2011. 医学書院, 東京.

研究分担者 : 橋本亮太

1. Takahashi H, Iwase M, Yasuda Y, Ohi Y, Fukumoto M, Iike N, Yamamori H, Nakahachi T, Ikezawa K, Azechi M, Canuet L, Ishii R, Kazui H, Hashimoto R, Takeda M. Relationship of Prepulse Inhibition to Temperament and Character in Healthy Japanese subjects. *Neuroscience Research* (in press)
2. Ohi K, Hashimoto R, Yasuda Y, Fukumoto M, Nemoto K, Ohnishi T, Yamamori H, Takahashi H, Iike N, Kamino K, Yoshida T, Azechi M, Ikezawa K, Tanimukai H, Tagami S, Morihara T, Okochi M, Tanaka T, Kudo T, Iwase M, Kazui H, Takeda M. The AKT1 gene is associated with attention and brain morphology in schizophrenia. *World J Biol Psychiatry*. (in press)
3. Ota M, Fujii T, Nemoto K, Tatsumi M, Moriguchi Y, Hashimoto R, Sato N, Iwata N, Kunugi H. A polymorphism of the ABCA1 gene confers susceptibility to schizophrenia and related brain changes. *Prog Neuropsychopharmacol Biol Psychiatry*. 35(8):1877-1883, 2011.12
4. Hashimoto R, Ohi K, Yasuda Y, Fukumoto M, Yamamori H, Kamino K, Morihara T, Iwase M, Kazui H, Takeda M. The KCNH2 gene is associated with neurocognition and the risk of schizophrenia. *World J Biol Psychiatry*. 2011.9 (epub)
5. Kazui H, Yoshida T, Takaya M, Sugiyama H, Yamamoto D, Kito Y, Wada T, Nomura K, Yasuda Y, Yamamori H, Ohi K, Fukumoto M, Iike N, Iwase M, Morihara T, Tagami S, Shimosegawa E, Hatazawa J, Ikeda Y, Uchida E, Tanaka T, Kudo T, Hashimoto R, Takeda M. Different Characteristics of Cognitive Impairment in Elderly Schizophrenia and Alzheimer's Disease in the Mild Cognitive Impairment Stage. *Dement Geriatr Cogn Disord* (in press)
6. Kushima I, Nakamura Y, Aleksic B, Ikeda M, Ito Y, Shiino T, Okochi T, Fukuo Y, Ujike H, Suzuki M, Inada T, Hashimoto R, Takeda M, Kaibuchi K, Iwata N, Ozaki N. Resequencing and Association Analysis of the KALRN and EPHB1 Genes And Their Contribution to Schizophrenia Susceptibility. *Schizophr Bull*, 2010.11(epub)

7. Ikezawa K, Ishii R, Iwase M, Kurimoto R, Canuet L, Takahashi H, Nakahachi T, Azechi M, Ohi K, Fukumoto M, Yasuda Y, Iike N, Takaya M, Yamamori H, Kazui H, OHashimoto R, Yoshimine T, Takeda M. Decreased alpha event-related synchronization in the left posterior temporal cortex in schizophrenia: A magnetoencephalography-beamformer study. *Neurosci Res.* 71(3):235-43, 2011.11
8. OHashimoto R, Ohi K, Yasuda Y, Fukumoto M, Yamamori H, Takahashi H, Iwase M, Okochi T, Kazui H, Saitoh O, Tatsumi M, Iwata N, Ozaki N, Kamijima K, Kunugi H and Takeda M. Variants of the *RELA* gene are associated with schizophrenia and their startle responses. *Neuropsychopharmacology*, 36(9):1921-1931, 2011.8
9. Yamamori H, OHashimoto R, Verrall L, Yasuda Y, Ohi K, Fukumoto M, Umeda-Yano S, Ito A, Takeda M. Dysbindin-1 and NRG-1 gene expression in immortalized lymphocytes from patients with schizophrenia, *J Hum Genet*, 56(7):478-83, 2011.7
10. Yasuda Y, OHashimoto R, Yamamori H, Ohi K, Fukumoto M, Umeda-Yano S, Mohri I, Ito A, Taniike M, Takeda M. Gene expression analysis in lymphoblasts derived from patients with autism spectrum disorder. *Molecular Autism*, 2:9, 2011.5
11. OHashimoto R, Ohi K, Yasuda Y, Fukumoto M, Yamamori H, Kamino K, Morihara T, Iwase M, Kazui H, Numata S, Ikeda M, Ueno S, Ohmori T, Iwata N, Ozaki N, Takeda M. No association between the *PCMI* gene and schizophrenia: a multi-center case-control study and a meta-analysis. *Schizophrenia Res*, 129:80-84, 2011.6
12. Yasuda Y, OHashimoto R, Ohi K, Fukumoto M, Umeda-Yano S, Yamamori H, Okochi T, Iwase M, Kazui H, Iwata N, Takeda M, Impact on schizotypal personality trait of a genome-wide supported psychosis variant of the *ZNF804A* gene, *Neurosci let*, 495:216-220, 2011.5
13. Hashimoto H, Shintani N, Tanida M, Hayata A, O Hashimoto R, Baba A. PACAP is Implicated in the Stress Axes, *Curr Pharm Des*, review, 17(10):985-9, 2011.4
14. Ohi K, Hashimoto R, Yasuda Y, Fukumoto M, Yamamori H, Umeda-Yano S, Kamino K, Ikezawa K, Azechi M, Iwase M, Kazui H, Kasai K, Takeda M. The *SIGMAR1* gene is associated with a risk of schizophrenia and activation of the prefrontal cortex. *Prog Neuropsychopharmacol Biol Psychiatry*, 35:1309-1315, 2011.4
15. Kobayashi K, Umeda-Yano S, Yamamori H, Takeda M, Suzuki H, O Hashimoto R. Correlated Alterations in Serotonergic and Dopaminergic Modulations at the Hippocampal Mossy Fiber Synapse in Mice Lacking Dysbindin. *PLoS One*, 23;6(3):e18113, 2011.3
16. Ikeda M, Aleksic B, Kinoshita Y, Okochi T, Kawashima K, Kushima I, Ito Y, Nakamura Y, Kishi T, Okumura T, Fukuo Y, Williams HJ, Hamshere ML, Ivanov D, Inada T, Suzuki M, O Hashimoto R, Ujike H, Takeda M, Craddock N, Kaibuchi K, Owen MJ, Ozaki N, O'Donovan MC, Iwata N. Genome-Wide Association Study of Schizophrenia in a Japanese Population. *Biol*

Psychiatry, 69(5):472-478, 2011.3.

17. Nihonmatsu-Kikuchi N, OHashimoto R, Hattori S, Matsuzaki S, Shinozaki T, Miura H, Ohota S, Tohyama M, Takeda M, Tatebayashi Y. Reduced rate of neural differentiation in the dentate gyrus of adult dysbindin null (sandy) mouse. PLoS One, 18;6(1):e15886, 2011.1

研究分担者：大森崇

1. 高橋佳苗, 長尾能雅, 足立由起, 森本剛, 市橋則明, 坪山直生, ○大森崇, 佐藤俊哉：高齢者におけるベンゾジアゼピン系薬の服用量変更と転倒との関連：急性期病院入院患者を対象にした解析, 薬剤疫学 **16**, 11-20, 2011.
2. H.Sakaguchi, N.Ota, ○T.Omori, H.Kuwahara, T.Sozu, Y.Takagi, Y.Takahashi, K.Tanigawa, M.Nakanishi, T.Nakamura, T.Morimoto, S.Wakuri, Y.Okamoto, M.Sakaguchi, T.Hayashi, T.Hanji, S.Watanabe: Validation study of the Short Time Exposure (STE) test to assess the eye irritation potential of chemicals, Toxicology in Vitro **25**, 796-809, 2011.

研究代表者：中込 和幸

1. Nakagome K, Mogami T. 9 Treatment-resistant schizophrenia. In Lauriello J and Pallanti S (eds.), *Clinical Manual for Treatment of Schizophrenia*. American Psychiatric Publishing, Washington DC, pp.341-380, 2012.
2. 樋口輝彦, 市川宏伸, 神庭重信, 朝田隆, 中込和幸, 編. 今日^の精神疾患治療指針, 医学書院, 東京, 2012.
3. 中込和幸. 5章 生活習慣, 心理・社会的側面と精神医学. 加藤進昌, 神庭重信, 笠井清登編, text 精神医学 psychiatry 改定4版, 南山堂, 東京, pp.76-87, 2012.
4. 中込和幸. 治療(抗精神病薬)選択肢変更の判断基準. 臨床精神薬理, 15, 181-187, 2012.
5. 中込和幸. 統合失調症:リハビリテーション期. 第2章 薬物療法で生活はどう変わる?:薬にできること・薬ができないこと 特集 生活の視点から薬物療法をとらえなおす. 精神科臨床サービス, 12: 24-28, 2012.
6. 尾鷲登志美, 中込和幸. 気分安定薬. 特集 双極性障害の治療. 精神科, 20: 391-397, 2012.
7. 池淵恵美, 中込和幸, 池澤聰, 三浦祥恵, 山崎修道, 根本隆洋, 樋代真一, 最上多美子. 統合失調症の社会的認知:脳科学と心理社会的介入の架橋を目指して. 精神神経学雑誌, 114(5): 489-507, 2012.
8. 野田隆政, 中込和幸. シンポジウムII 精神疾患の診断ツールとしての光トポグラフィ. 認知神経科学, 14(1): 35-41, 2012.
9. 最上多美子, 池澤聰, 兼子幸一, 中込和幸. 認知矯正療法 NEAR について. Schizophrenia Frontier, 13(1), 24-27, 2012.
10. 中込和幸. 統合失調症の社会的転帰の改善を踏まえた認知機能障害への治療的アプローチ - 社会認知と動機づけ -. Schizophrenia Frontier, 13(1), 34-41, 2012.
11. Ikezawa S, Mogami T, Hayami Y, Sato I, Kato T, Kimura I, Pu S, Kaneko K, Nakagome K. The pilot study of a Neuropsychological Educational Approach to Cognitive Remediation for patients with schizophrenia in Japan. Psychiatry Res. 195: 107-110, 2012.
12. Kobayashi H, Iwata M, Mitani H, Yamada T, Nakagome K, Kaneko K. Valproic acid improves the tolerance for the stress in learned helplessness rats. Neurosci Res. 72(4): 355-363, 2012.
13. Iwata M, Hazama GI, Nakagome K. Depressive state due to isolated adrenocorticotrophic hormone deficiency underlies school refusal. Psychiatry Clin Neurosci. 66(3): 243-244, 2012.

14. Yamada T, Pu S, Yokoyama K, Matsumura H, Mitani H, Kaneko K, Nakagome K. Fish consumption is positively associated with social functioning: A cross-sectional study in male Japanese workers. *Psychiatry Res*, 200(2-3): 1038-1040
15. Pu S, Yamada T, Yokoyama K, Matsumura H, Mitani H, Adachi A, Kaneko K, Nakagome K. Reduced prefrontal cortex activation during the working memory task associated with poor social functioning in late-onset depression: multi-channel near-infrared spectroscopy study. *Psychiatry Res*, 203(2-3): 222-228, 2012.
16. Pu S, Nakagome K, Yamada T, Yokoyama K, Matsumura H, Mitani H, Adachi A, Nagata I, Kaneko K. The relationship between the prefrontal activation during a verbal fluency task and stress-coping style in major depressive disorder: A near-infrared spectroscopy study. *J Psychiatr Res*, 46(11): 1427-1434, 2012.

研究分担者：武田 伸一

1. Ito M, Suzuki Y, Okada T, Fukudome T, Yoshimura T, Masuda A, Takeda S, Krejci E, Ohno K: Protein-anchoring strategy for delivering acetylcholinesterase to the neuromuscular junction. *Mol Ther*. 2012 Jul;20(7):1384-92. doi: 10.1038/mt.2012.34. PMID: 22371845
2. Yokota T, Nakamura A, Nagata T, Saito T, Kobayashi M, Aoki Y, Echigoya Y, Partridge T, Hoffman EP, Takeda S : Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. *Nucleic Acid Ther*. 2012 Oct;22(5):306-15. doi: 10.1089/nat.2012.0368. Epub 2012 Aug 13.
3. Aoki Y, Yokota T, Nagata T, Nakamura A, Tanihata J, Saito T, Duguez M. R. S , Nagaraju K, Hoffman P. E, Partridge T, Takeda S: Body-wide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. *Proc Natl Acad Sci USA*. 2012 August 21 109(34) : 13763-13768. doi: 10.1073/pnas.1204638109
4. Yamaguchi M, Ogawa R, Watanabe Y, Uezumi A, Miyagoe-Suzuki Y, Tsujikawa K, Yamamoto H, Takeda S, Fukada S : Calcitonin receptor and Odz4 are differently expressed in Pax7-positive cells during skeletal muscle regeneration. *J Mol Histol*. 2012 Oct;43(5):581-7. doi: 10.1007/s10735-012-9421-3. Epub 2012 May 5.
5. Ito N, Ruegg UT, Kudo A, Miyagoe-Suzuki Y, Takeda S: Activation of calcium signaling through Trpv1 by nNOS and peroxynitrite as a key trigger of skeletal muscle hypertrophy. *Nat Med*. 2013 Jan;19(1):101-6. doi: 10.1038/nm.3019. Epub 2012 Dec 2
6. Ito T, Ogawa R, Uezumi A, Ohtani T, Watanabe Y, Tsujikawa K, Miyagoe-Suzuki Y, Takeda S, Yamamoto H, Fukada SI.: Imatinib attenuates dystrophic condition in severe mouse dystrophy and inhibits both proliferation and fibrosis-marker expression in muscle mesenchymal progenitors. *Neuromuscul Disord*. 2013 Jan 9. pii: S0960-8966(12)00676-1. doi: 10.1016/j.nmd.2012.10.025. [Epub ahead of print]
7. Kimura K, Takenaka K, Ebihara A, Uno K, Morita H, Nakajima T, Ozawa T, Aida I, Yonemochi

- Y, Higuchi S, Motoyoshi Y, Mikata T, Uchida I, Ishihara T, Komori T, Kitao R, Nagata T, Takeda S, Yatomi Y, Nagai R, Komuro I. : Prognostic impact of left ventricular noncompaction in patients with Duchenne/Becker muscular dystrophy - Prospective multicenter cohort study. **Int J Cardiol.** 2013 Jan 17. pii: S0167-5273(12)01687-7. doi: 10.1016/j.ijcard.2012.12.058. [Epub ahead of print]
8. Rayavarapu S, Coley W, Cakir E, Jahnke V, Takeda S, Aoki Y, Gordish-Dressman H, Jaiswal JK, Hoffman EP, Brown KJ, Hathout Y, Nagaraju K. : Identification of disease specific pathways using in vivo SILAC proteomics in dystrophin deficient mdx mouse. **Mol Cell Proteomics.** 2013 Jan 7. [Epub ahead of print]
9. Tremblay JP, Xiao X, Aartsma-Rus A, Barbas C, Blau HM, Bogdanove AJ, Boycott K, Braun S, Breakefield XO, Bueren JA, Buschmann M, Byrne BJ, Calos M, Cathomen T, Chamberlain J, Chuah M, Cornetta K, Davies KE, Dickson JG, Duchateau P, Flotte TR, Gaudet D, Gersbach CA, Gilbert R, Glorioso J, Herzog RW, High KA, Huang W, Huard J, Joung JK, Liu D, Liu D, Lochmüller H, Lustig L, Martens J, Massie B, Mavilio F, Mendell JR, Nathwani A, Ponder K, Porteus M, Puymirat J, Samulski J, Takeda S, Thrasher A, Vandendriessche T, Wei Y, Wilson JM, Wilton SD, Wolfe JH, Gao G. : Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases. **Mol Ther.** 2013 Feb;21(2):266-8. doi: 10.1038/mt.2013.4.

研究分担者：山田光彦

1. Saitoh A, Yamada M: Antidepressant-like effects of δ opioid receptor agonists in animal models. *Curr Neuropharmacol* 10(3): 231-238, 2012.
2. Kodaka M, Inagaki M, Poštuvan V, Yamada M: Exploration of factors associated with social worker attitudes toward suicide. *Int J Soc Psych*, Epub ahead of print, 2012.
3. Ohtsuki T, Kodaka M, Sakai R, Ishikura F, Watanabe Y, Mann A, Haddad M, Yamada M, Inagaki M: Attitudes toward depression among Japanese non-psychiatric medical doctors: a cross-sectional study. *BMC Res Notes* 16(5): 441, 2012.
4. Shimodera S, Kato T, Sato H, Miki K, Shinagawa Y, Kondo M, Fujita H, Morokuma I, Ikeda Y, Akechi T, Watanabe N, Yamada M, Inagaki M, Yonemoto N, Furukawa T.A : The first 100 patients in the SUN(^_^)D trial (strategic use of new generation antidepressants for depression): examination of feasibility and adherence during the pilot phase. *Trials* 13(1): 80, 2012.
5. Sugiyama A, Saitoh A, Iwai T, Takahashi K, Yamada M, Sasaki-Hamada S, Oka J, Inagaki M, Yamada M: Riluzole produces distinct anxiolytic-like effects in rats without the adverse effects associated with benzodiazepines. *Neuropharmacol* 62: 2489-2498 ,2012.
6. Takahashi K, Saitoh A, Yamada M, Iwai T, Inagaki M, Yamada M: Dexamethasone indirectly induces Ndr2 expression in rat astrocytes. *J Neurosci Res* 90: 160-166, 2012.

7. Iwai T, Saitoh A, Yamada M, Takahashi K, Hashimoto E, Ukai W, Saito T, Yamada M: Rhotekin modulates differentiation of cultured neural stem cells to neurons. *J Neurosci Res* 90: 1359-1366, 2012.
8. 斎藤顕宜, 山田光彦: グルタミン酸神経調節薬リルゾールによる新世代抗うつ薬の開発の可能性. *ストレス科学* 27(1): 98-103, 2012.
9. 山田光彦: 精神科領域における臨床的研究の推進を目指して. *こころの健康と病気* 2011, 監修 財団法人 精神・神経科学振興財団, pp29-35, 2012.
10. 稲垣正俊, 大槻露華, 山田光彦: かかりつけ病院によるうつ病の発見と治療への導入. *こころの健康と病気* 2011, 監修 財団法人 精神・神経科学振興財団, pp36-44, 2012.
11. 山田光彦: 精神科ポケット辞典 新訂版, 弘文堂, 東京, 2012.
12. 斎藤顕宜, 稲垣正俊, 山田光彦: 「リルゾールの抗うつ様・抗不安様効果」気分障害の薬理・生化学～うつ病の脳内メカニズム研究: 進歩と挑戦～. 躁うつ病の薬理・生化学的研究懇話会編, 医薬ジャーナル社, 東京, pp93-94, 2012.
13. 山田光彦, 稲垣正俊(分担執筆), 小山 司, 樋口輝彦編: 希死念慮・自殺企図がうかがえるうつ病患者へのミルタザピン処方. *ミルタザピンのすべて*, 先端医学社, 東京, pp106-109, 2012.
14. 斎藤顕宜, 山田光彦, : 抗精神病薬開発の歴史と展望. 中村純編: *抗精神病薬完全マスター*. 医学書院, 東京, 2012.

研究分担者: 伊藤弘人

1. Ito H, Okumura Y, Higuchi T, Tan CH, Shinfuku N: International variation in antipsychotic prescribing for schizophrenia: Pooled results from the research on East Asia psychotropic prescription (reap) studies. *Open Journal of Psychiatry* 2 : 340-346, 2012.
2. Noda T, Sugiyama N, Ito, Soininen P, Putkonen H, Sailas E, Joffe G: Secluded/restrained patients' perception of their treatment: validity and reliability of a questionnaire. *Psychiatry and Clinical Neurosciences* 66 : 397-404, 2012.
3. Noda T, Nijman H, Sugiyama N, Tsujiwaki K, Putkonen H, Sailas E, Kontio R, Ito H, Joffe G : Factors Affecting Assessment of Severity of Aggressive Incidents: Using the Staff Observation Aggression Scale-Revised (SOAS-R) in Japan. *Journal of Psychiatric and Mental Health Nursing* 19 : 770-775, 2012.
4. Okumura Y, Shimizu S, Ishikawa KB, Matsuda S, Fushimi K, Ito H: Characteristics, procedural differences, and costs of inpatients with drug poisoning in acute care hospitals in Japan. *General Hospital Psychiatry* 34: 681-685, 2012.
5. Okumura Y, Shimizu S, Ishikawa KB, Matsuda S, Fushimi K, Ito H: Comparison of emergency hospital admissions for drug poisoning and major diseases: a retrospective observational study using a nationwide administrative discharge database. *BMJ Open* 2: e001857-, 2012.

6. Ito H, Seotya Y, Suzuki Y. Lessons learned in developing community mental health care in East and South East Asia. *World Psychiatry* 11: 186-190, 2012.

研究分担者：村田美穂

1. Mori-Yoshimura M, Oya Y, Hayashi YK, Noguchi S, Nishino I, Murata M. Respiratory dysfunction in patients severely affected by GNE myopathy (distal myopathy with rimmed vacuoles) *Neuromuscul Disord* 2013;23:84-88
2. Sharma M, Ioannidis JP, Aasly JO, Annesi G, Brice A, Bertram L, Bozi M, Barcikowska M, Crosiers D, Clarke CE, Facheris MF, Farrer M, Garraux G, Gispert S, Auburger G, Vilariño-Güell C, Hadjigeorgiou GM, Hicks AA, Hattori N, Jeon BS, Jamrozik Z, Krygowska-Wajs A, Lesage S, Lill CM, Lin JJ, Lynch T, Lichtner P, Lang AE, Libioulle C, Murata M, Mok V, Jasinska-Myga B, Mellick GD, Morrison KE, Meitnger T, Zimprick A, Opala G, Pramstaller PP, Pichler I, Park SS, Quattrone A, Rogaeva E, Ross OA, Stefanis L, Stockton JD, Satake W, Silburn PA, Strom TM, Thenus J, Tan EK, Toda T, Tomiyama H, Uitti RJ, Van Broeckhoven C, Wirdefeldt K, Wszolek Z, Xiromerisiou G, Yomono HS, Yueh KC, Zhao Y, Gasser T, Maraganore D, Krüger R; on behalf of GEOPD consortium. A multi-centre clinic-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. *J Med Genet* 2012;49(11):721-726
3. Hattori N, Fujimoto K, Kondo T, Murata M, Stacy M. Patient perspectives on Parkinson's disease therapy in Japan and the United States: results of two patient surveys *Patient Related Outcome Measures* 2012;3(31):31-38
4. Mori-Yoshimura M, Okuma A, Oya Y, Fujimura-Kiyono C, Matsuura K, Takemura A, Malicdan MC, Hayashi YK, Nonaka I, Murata M, Nishino I. Clinicopathological features of centronuclear myopathy in Japanese populations harboring mutations in dynamin 2. *Clin Neurosurg* 2012;114:678-683
5. Yamamoto T, Chihara N, Mori-Yoshimura M, Murata M. Videofluorographic detection of anti-muscle-specific kinase-positive myasthenia gravis *Am J Otolaryngology* 2012;33:758-761
6. Sato W, Tomita A, Ichikawa D, Lin Y, Kishida H, Miyake S, Ogawa M, Okamoto T, Murata M, Kuroiwa Y, Aranami T, Yamamura T. CCR2⁺CCR5⁺ T Cells Produce Matrix Metalloproteinase-9 and Osteopontin in the Pathogenesis of Multiple Sclerosis *The Journal of Immunology* 2012;5057-5065
7. Kawazoe T, Araki M, Lin Y, Ogawa M, Okamoto T, Yamamura T, Wakakura M, Murata M. New-Onset Type 1 Diabetes Mellitus and Anti-Aquaporin-4 Antibody Positive Optic Neuritis Associated with Type 1 Interferon Therapy for Chronic Hepatitis C *Intern Med* 2012; 51:2625-2629
8. Mori-Yoshimura M, Monma K, Suzuki N, Aoki M, Kumamoto T, Tanaka K, Tomimitsu H,

- Nakano S, Sonoo M, Shimizu J, Sugie K, Nakamura H, Oya Y, Yukiko K, Hayashi, May Christine V, Malicdan, Noguchi s, Murata M, Nishino I. Heterozygous UDP-GlcNAc 2-epimerase and N-acetylmannosamine kinase domain mutations in the GNE gene result in a less severe GNE myopathy phenotype compared to homozygous N-acetylmannosamine kinase domain mutations J Neurol Sci 2012;318:100-105
9. Kandori A, Yamamoto T, Sano Y, Oonuma M, Miyashita T, Murata M, and Sakoda S. Simple Magnetic Swallowing Detection System IEEE SENSORSJOURNAL 2012;12(4):805-811
 10. Furusawa Y, Mukai Y, Kobayashi Y, Sakamoto T, Murata M. Role of the external oblique muscle in upper camptocormia for patients with Parkinson's disease. Mov.Dis. 2012;27:802-803
 11. Yamamoto T, Ikeda K, Usui H, Miyamoto M, Murata M. Validation of the Japanese translation of the Swallowing Disturbance Questionnaire in parkinson's disease patients. Qual Life Res 2012;21:1299-1303
 12. 池田謙輔,岡本智子,山村隆,大澤勲,古寺理恵,村田美穂. インターフェロンβ—1 b 長期治療中にネフローゼ症候群を合併した多発性硬化症の2例 臨床神経 2012;53(1):19-23
 13. 山本敏之,臼井晴美,新庄孝子,市川直美,三好智佳子,村田美穂. 問診によるパーキンソン病患者の誤嚥の評価 嚥下医学 2012:90-98
 14. 村田美穂. パーキンソン病の診断と治療 パーキンソン病治療薬：L-dopa と関連薬剤 GP・レジデントのためのパーキンソン病テキストブック 山本光利編著 アルタ出版 東京 2012, p p 111-119
 15. 村田美穂 やさしいパーキンソン病の自己管理. 改訂版 村田美穂編著, 医薬ジャーナル社, 大阪, 2012
 16. 村田美穂. ハンチントン病 今日の精神疾患治療指針 樋口輝彦,市川宏伸,神庭重信,朝日 隆,中込和幸編 医学書院 東京 2012,404-407
 17. 岡本智子,村田美穂. パーキンソン病 今日の精神疾患治療指針 樋口輝彦,市川宏伸,神庭重信,朝日 隆,中込和幸編 医学書院 東京 2012,pp400-404
 18. 古澤嘉彦,村田美穂. パーキンソン病と姿勢異常 Medical Practice 2013;30(1):109-111
 19. 村田美穂,北浦 円. パーキンソン病 高まる L-ドパ再評価の機運 クレデンシャル 2012;49:14-20
 20. 村田美穂. 高齢者パーキンソン病に対する治療の考え方 日本医事新報 東京 2012,4.7 (4589) :78-82

研究分担者：後藤雄一

1. Takeshita E, Nakagawa E, Nakatani K, Sasaki M, Goto Y. Novel AGTR2 missense mutation in a Japanese boy with severe mental retardation, pervasive developmental disorder, and epilepsy. *Brain Dev* 34: 776-779, 2012.
2. Sangatsuda Y, Nakamura M, Tomiyasu A, Deguchi A, Toyota Y, Goto Y, Nishino I, Ueno A,

- Sano A. Heteroplasmic m.1624C>T mutation of the mitochondrial tRNA-Val gene in a proband and his mother with repeated consciousness disturbances. *Mitochondrion* 12: 617-622, 2012
3. Takeshita E, Saito Y, Nakagawa E, Komaki H, Sugai K, Sasaki M, Nezu A, Kitamura J, Masayuki I, Sawano Y, Goto Y. Late-onset mental deterioration and fluctuating dystonia in a female patient with a truncating MECP2 mutation. *J Neurol Sci* 308: 168-172, 2012

研究分担者：功刀浩

1. Hori H, Kunugi H: The efficacy of pramipexole, a dopamine receptor agonist, as an adjunctive treatment in treatment-resistant depression: an open-label trial. *ScientificWorldJournal* 2012; 372474

研究分担者：米本直裕

1. Inagaki M, Ohtsuki T, Yonemoto N, Oikawa Y, Kurosawa M, Muramatsu K, Furukawa TA, Yamada M. (2013) Prevalence of depression among outpatients visiting a general internal medicine polyclinic in rural Japan. *Gen Hosp Psychiatry*. 2013 Jan 22. [Epub ahead of print]
2. Matsuoka Y, Nishi D, Yonemoto N, Hamazaki K, Matsumura K, Noguchi H, Hashimoto K, Hamazaki T (2013) Tachikawa project for prevention of posttraumatic stress disorder with polyunsaturated fatty acid (TPOP): study protocol for a randomized controlled trial. *BMC Psychiatry*. 2013 Jan 5;13(1):8.
3. Ikeda M, Ioka T, Ito Y, Yonemoto N, Nagase M, Yamao K, Miyakawa H, Ishii H, Furuse J, Sato K, Sato T, Okusaka T (2013) A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys*. 2013 Jan 1;85(1):163-9.
4. Iwami T, Kitamura T, Kawamura T, Mitamura H, Nagao K, Takayama M, Seino Y, Tanaka H, Nonogi H, Yonemoto N, Kimura T; Japanese Circulation Society Resuscitation Science Study (JCS-ReSS) Group.(2012) Chest compression-only cardiopulmonary resuscitation for out-of-hospital cardiac arrest with public-access defibrillation: a nationwide cohort study. *Circulation*. 2012 Dec 11;126(24):2844-51
5. Kitamura T, Iwami T, Kawamura T, Nitta M, Nagao K, Nonogi H, Yonemoto N, Kimura T; Japanese Circulation Society Resuscitation Science Study Group.(2012) Nationwide improvements in survival from out-of-hospital cardiac arrest in Japan. *Circulation*. 2012 Dec 11;126(24):2834-43.
6. Nishi D, Noguchi H, Yonemoto N, Nakajima S, Kim Y, Matsuoka Y. (2012) Incidence and Prediction of Post-Traumatic Stress Disorder at 6 Months After Motor Vehicle Accidents in Japan. *Psychosomatics*. 2012 Nov 27. [Epub ahead of print]

7. Usuki M, Matsuoka Y, Nishi D, Yonemoto N, Matsumura K, Otomo Y, Kim Y, Kanba S.(2012) Potential impact of propofol immediately after motor vehicle accident on later symptoms of posttraumatic stress disorder at 6-month follow up: a retrospective cohort study. *Crit Care*. 2012 Oct 28;16(5):R196.
8. Shimodera S, Kato T, Sato H, Miki K, Shinagawa Y, Kondo M, Fujita H, Morokuma I, Ikeda Y, Akechi T, Watanabe N, Yamada M, Inagaki M, Yonemoto N, Furukawa TA; SUN(^_^)D Investigators. (2012) The first 100 patients in the SUN(^_^)D trial (strategic use of new generation antidepressants for depression): examination of feasibility and adherence during the pilot phase. *Trials*. 2012 Jun 8;13:80.
9. Soga T, Nagao K, Sawano H, Yokoyama H, Tahara Y, Hase M, Otani T, Shirai S, Hazui H, Arimoto H, Kashiwase K, Kasaoka S, Motomura T, Kuroda Y, Yasuga Y, Yonemoto N, Nonogi H; J-PULSE-Hypo Investigators.(2012) Neurological benefit of therapeutic hypothermia following return of spontaneous circulation for out-of-hospital non-shockable cardiac arrest. *Circ J*. 2012;76(11):2579-85.
10. Maruyama H, Kitajima H, Yonemoto N, Fujimura M. Frequent use of fresh frozen plasma is a risk factor for venous thrombosis in extremely low birth weight infants: a matched case-control study. *Acta Med Okayama*. 2012;66(1):61-6.

研究分担者：小牧宏文

1. Yonekawa T, Okomaki H, Saito Y, Takashima H, Sasaki M. Congenital Hypomyelinating Neuropathy Attributable to a De Novo p.Asp61Asn Mutation of the Myelin Protein Zero Gene. *Pediatr Neurol*. 2013 ;48:59-62.
2. Ishiyama A, Okomaki H, Saito T, Saito Y, Nakagawa E, Sugai K, Itagaki Y, Matsuzaki K, Nakura M, Nishino I, Goto YI, Sasaki M. Unusual exocrine complication of pancreatitis in mitochondrial disease. *Brain Dev*. in press.
3. Yonekawa T, Okomaki H, Saito Y, Sugai K, Sasaki M. Peripheral nerve abnormalities in pediatric patients with spinal muscular atrophy. *Brain Dev*. 2013;35:165-71.
4. Kawabata T, Okomaki H, Saito T, Saito Y, Nakagawa E, Sugai K, Sasaki M, Hayashi YK, Nishino I, Momomura M, Kizawa T, Imagawa T, Yokota S. A pediatric patient with myopathy associated with antibodies to a signal recognition particle. *Brain Dev*. 2012;34:877-80.
5. Hattori A, Okomaki H, Kawatani M, Sakuma H, Saito Y, Nakagawa E, Sugai K, Sasaki M, Hayashi YK, Nonaka I, Nishino I. A novel mutation in the LMNA gene causes congenital muscular dystrophy with dropped head and brain involvement. *Neuromuscul Disord*. 2012;22:149-51.
6. Mizuno T, Okomaki H, Sasaki M, Takanoha S, Kuroda K, Kon K, Mamiya S, Yoshioka M,

- Yatabe K, Mikata T, Ishihara T, Nakajima T, Watanabe H, Konagaya M, Mitani M, Konishi T, Tokita Y, Fukuda K, Tatara K, Maruta K, Imamura S, Shimazaki R, Ishikawa K, Saito T, Shinno S. Efficacy and tolerance of gastrostomy feeding in Japanese muscular dystrophy patients. *Brain Dev.* 2012;34:756-62.
7. Sukigara S, Liang WC, Komaki H, Fukuda T, Miyamoto T, Saito T, Saito Y, Nakagawa E, Sugai K, Hayashi YK, Sugie H, Sasaki M, Nishino I. Muscle glycogen storage disease 0 presenting recurrent syncope with weakness and myalgia. *Neuromuscul Disord.* 2012;22:162-5.
 8. 苛原香, 小牧宏文, 本田涼子, 奥村彰久, 白石一浩, 小林悠, 東慶輝, 中田智彦, 大矢寧, 佐々 征行. 本邦における先天性筋無力症候群の臨床的特徴. *脳と発達*(0029-0831)44 巻 6 号 Page450-454(2012.11)
 9. 竹下絵里, 小牧宏文. 【ミトコンドリア病-up to date】 代表的なミトコンドリア病 Leigh 脳症(解説/特集). *Clinical Neuroscience* 30,9, 1030-1033,2012.
 10. 小牧宏文. 小児の診療手技 100 筋生検 *小児科診療* 75,276-278,2012.
 11. 小牧宏文. 小児の診療手技 100 末梢神経生検 *小児科診療* 75,279-280,2012.
 12. 小牧宏文. 症候・疾患と検査・診断 神経筋疾患の診断 *小児神経学の進歩* 41,69-77,2012.
 13. 小牧宏文. 筋ジストロフィーの best supportive care *日本小児科学会雑誌* 116,655-665,2012.
 14. 石山昭彦, 小牧宏文. 【小児慢性疾患の生活指導-最新の知見から-】 日常生活における管理・指導 神経・筋疾患 先天性ミオパチー. *小児科臨床*.65,4,839-846,2012.

研究分担者：松岡豊

1. Matsuoka Y, Nishi D, Su K-P: It's high time to challenge a collaboration of omega-3s in the prevention. Symposium "Developing Clinical Research Consortium (Matsuoka Y and Jong-Woo Paik)". The 15th Pacific Rim College of Psychiatrists Scientific Meeting. (Seoul, Korea) 2012/10/25-27
2. Heron-Delaney M, Kenardy J, Charlton E, Matsuoka Y: A Systematic Review of Predictors of Posttraumatic Stress Disorder (PTSD) for Road Traffic Crash Survivors. Symposium "Comorbidity and phenomenology". The 17th Australian Conference on Traumatic Stress. (Perth, Australia) 2012/9/6-8
3. Matsuoka Y, Nishi D, Nakaya N, Sone T, Noguchi H, Hamazaki K, Hamazaki T, Koido Y: Peritraumatic distress, watching television and posttraumatic stress symptoms among rescue workers after the Great East Japan Earthquake. 12th International Congress of Behavioral Medicine, (Budapest, Hungary) 2012/8-29-9/1
4. Matsuoka Y, Nishi D, Koido Y, Nakaya N, Sone, T, Noguchi H, Hamazaki K, Hamazaki T: Fish Oil for Attenuating Posttraumatic Stress Symptoms among Rescue Workers after the Great East

- Japan Earthquake: A Randomized Controlled Trial. 71st APS Annual Meeting. (Miami, Florida) 2013/3/13-16
5. Nishi D, Koido Y, Nakaya N, Sone T, Noguchi H, Hamazaki K, Hamazaki T, Matsuoka Y: Peritraumatic distress, watching television and posttraumatic stress symptoms among rescue workers after the Great East Japan Earthquake. 71st APS Annual Meeting. (Miami, Florida) 2013/3/13-16
 6. Usuki M, Matsuoka Y, Nishi D, Yonemoto N, Matsumura K, Otomo Y, Kim Y, Kanba S: Potential impact of propofol after motor vehicle accident on later symptoms of posttraumatic stress disorder. 71st APS Annual Meeting. (Miami, Florida) 2013/3/13-16
 7. Heron-Delaney M, Kenardy J, Charlton E, Matsuoka Y: A Systematic Review of Predictors of Posttraumatic Stress Disorder (PTSD) for Road Traffic Crash Survivors. International Society for Traumatic Stress Studies 28th Annual Meeting. (Los Angeles) 2012/11/1-3
 8. Nishi D, Koido Y, Nakaya N, Sone T, Noguchi H, Hamazaki K, Hamazaki T, Matsuoka Y: Fish oil plus psychoeducation versus psychoeducation alone for attenuating posttraumatic stress symptoms among rescue workers after the Great East Japan Earthquake: A randomized controlled trial. 12th International Congress of Behavioral Medicine, (Budapest, Hungary) 2012/8-29-9/1
 9. Matsuoka Y, Nishi D, Nakaya N, Sone T, Noguchi H, Hamazaki K, Hamazaki T, Koido Y: Attenuating posttraumatic stress symptoms with omega-3 polyunsaturated fatty acids among rescue workers after the Great East Japan Earthquake: Feasibility of a filed randomized controlled trial. 10th Congress of the International Society for the Study of Fatty Acids and Lipids. (Vancouver, Canada) 2012/5/26-30
 10. Nishi D, Koido Y, Nakaya N, Sone T, Noguchi H, Hamazaki K, Hamazaki T, Matsuoka Y: Fish oil for attenuating posttraumatic stress symptoms among rescue workers after the Great East Japan Earthquake: A randomized controlled trial. 10th Congress of the International Society for the Study of Fatty Acids and Lipids. (Vancouver, Canada) 2012/5/26-30
 11. 松岡豊: 魚油に秘められた PTSD 予防の可能性. 第 2 回日本情動学会大会, 東京, 2012/12/22
 12. 松岡豊: 研究倫理を学ぶ仕組みとしての臨床研究研修制度. 徳島大学倫理委員会 30 周年記念研究倫理シンポジウム, 徳島, 2012/12/14
 13. 松岡豊: 研究する人なら知っておきたい研究倫理の歴史と基本原則. 第 2 回臨床研究教育セミナー「臨床研究入門講座その 2」, 第 53 回日本児童青年精神医学会総会, 東京, 2012/11/1
 14. 松岡豊: 魚油でトラウマからここを守れるか. ランチョンセミナー, 第 66 回日本栄養・食糧学会, 仙台, 2012/5/19
 15. 松岡豊: もっと英語論文を書こう. 臨床研究で医学英語論文を書いてみよう (オーガ

- ナイザー：松岡豊). 第 25 回日本総合病院精神医学会総会. 東京, 2012/11/30-12/1
16. 松岡豊： ω 3 系脂肪酸による心的外傷後ストレス障害予防の可能性. シンポジウム「多価不飽和脂肪酸による精神・神経疾患の予防・治療の可能性を探る (座長：橋本道男, 松岡豊)」第 86 回日本薬理学会年会. 福岡, 2013/3/21-23
 17. 松岡豊, 西大輔： ω 3 系脂肪酸による PTSD 予防への挑戦. シンポジウム「不安障害における神経画像・臨床研究の最前線 (座長：松岡豊, 中尾智博)」第 4 回日本不安障害学会学術総会. 東京, 2012/2/4-5
 18. 野口普子, 西大輔, 金吉晴, 小西聖子, 松岡豊：交通外傷患者の過去のトラウマ体験が認知的評価に及ぼす影響についての検討. 第 5 回日本不安障害学会学術総会. 札幌, 2013/2/2-3
 19. 松岡豊, 西大輔, 中谷直樹, 曾根稔雅, 野口普子, 浜崎景, 浜崎智仁, 小井土雄一：東日本大震災における災害医療救援者の放射線被ばくに対する心配と精神的苦痛の関連日本疫学会総会. 大阪, 2013/1/24-26
 20. 西大輔, 中谷直樹, 曾根稔雅, 野口普子, 浜崎景, 浜崎智仁, 小井土雄一, 松岡豊：東日本大震災の医療救援者におけるオメガ 3 系脂肪酸の PTSD 症状に対する有効性の検討. 第 23 回日本疫学会学術総会. 大阪, 2013/1/24-26
 21. 西大輔, 中谷直樹, 曾根稔雅, 野口普子, 浜崎景, 浜崎智仁, 小井土雄一, 松岡豊：東日本大震災の医療救援者における PTSD 症状の予測因子に関する検討. 第 23 回日本疫学会学術総会. 大阪, 2013/1/24-26
 22. 永岑光恵, 野口普子, 松岡豊：情動記憶形成に及ぼすコルチゾール日内リズムの影響. 第 2 回日本情動学会大会. 東京, 2012/12/22
 23. 野口普子, 西大輔, 中島聡美, 小西聖子, 金吉晴, 松岡豊：交通事故に関する認知的評価と外傷後ストレス障害 (PTSD) に関する縦断研究. 第 2 回日本情動学会大会. 東京, 2012/12/22
 24. 野口普子, 西大輔, 中島聡美, 小西聖子, 金吉晴, 松岡豊：交通事故に関する認知的評価と外傷後ストレス障害に関する縦断研究. 第 12 回日本認知療法学会. 東京, 2012/11/23-24
 25. 野口普子, 松村健太, 山越健弘, 松岡豊：魚食習慣と精神的ストレス負荷時の心臓血管系反応. 日本脂質栄養学会. 相模原, 2012/9/7-8
 26. 臼杵理人, 西大輔, 松岡豊：うつ病患者に亜昏迷状態、精神運動興奮状態で発症した可逆性後頭葉白質脳症の 1 症例. 第 25 回日本総合病院精神医学会総会. 東京, 2012/11/30-12/1
 27. 野口普子, 西大輔, 中島聡美, 小西聖子, 金吉晴, 松岡豊：交通外傷患者の外傷体験に対する認知的評価と外傷後ストレス障害についての縦断研究. 第 25 回日本総合病院精神医学会総会. 東京, 2012/11/30-12/1

研究分担者：中川敦夫

1. Takagi S, Iwata K, Nakagawa A. Relationship between body mass index and blood pressure elevation during electroconvulsive therapy. *J Clin Anesth*. 2012 Feb;24(1):33-7
2. 櫻井準, 中川敦夫：【生活の視点から薬物療法をとらえなおす:薬にできること・できないこと】(第5章)薬についてのよくある疑問に答える 薬は中止できるの?(抗精神病薬、抗うつ薬、抗不安薬), *精神科臨床サービス*, 12(1) : 115-116, 2012
3. 田村法子, 中川敦夫:うつ病の認知行動療法—わが国における実証的研究, *医学のあゆみ*, 242(6/7) : 501-504, 2012
4. 坂本友香, 中川敦夫:大うつ病性障害—薬剤師に必要な精神疾患の基礎知識—, *日本病院薬剤師会雑誌*, 48(11) : 1331-1334, 2012
5. Nakagawa A:Conducting depression CBT trial in Japan. 15th Pacific Rim College of psychiatrists Scientific Meeting, Korea, 25 Oct 2012.
6. 中川敦夫:うつ病の症状評価実施：その課題と対応, 第22回日本臨床精神神経薬理学会・第42回日本神経精神薬理学会合同年会, 栃木, 2012年10月
7. 中川敦夫:臨床研究の倫理を考える, 第22回日本臨床精神神経薬理学会・第42回日本神経精神薬理学会合同年会, 栃木, 2012年10月
8. 橋本保彦, 中川敦夫, 堀輝, 加瀬浩二, 毛利彰宏:スタディーグループ「処方設計」, 第22回日本臨床精神神経薬理学会・第42回日本神経精神薬理学会合同年会, 栃木, 2012年10月
9. 中川敦夫:臨床研究の歴史、意義、研究の形式化, 第25回日本総合病院精神医学会, 東京, 2012年11月

研究分担者：橋本亮太

1. Furukawa M, Tochigi M, Otowa T, Arinami T, Inada T, Ujike H, Watanabe Y, Iwata N, Itokawa M, Kunugi H, **Hashimoto R**, Ozaki N, Kakiuchi C, Kasai K, Sasaki T, An association analysis of the cardiomyopathy-associated 5(CMYA5) gene with schizophrenia in a Japanese population. *Psychiatr Genet* (in press)
2. Kitaichi Y, **Hashimoto R**, Inoue T, Abekawa T, Kakuta A, Hattori S, Koyama T. Abnormalities in extracellular glycine and glutamate levels in the striatum of sandy mice. *Acta Neuropsychiatrica* (in press)
3. Aleksic B., Kushima I, **Hashimoto R**, Ohi K, Ikeda M, Yoshimi A, Nakamura Y, Ito Y, Okochi T, Fukuo Y, Yasuda Y, Fukumoto M, Yamamori H, Ujike H, Suzuki M, Inada T, Takeda M, Kaibuchi K, Iwata N, Ozaki N. Analysis of the VAV3 as candidate gene for schizophrenia: evidences from voxel based morphometry and mutation screening. *Schizophrenia Bulletin*. e-pub
4. Ota M, Sato N, Ishikawa M, Hori H, Sasayama D, Hattori K, Teraishi T, Obu S, Nakata Y, Nemoto K, Moriguchi Y, **Hashimoto R**, Kunugi H. Discrimination of schizophrenic females from healthy women using multiple structural brain measures obtained with

- voxel-based morphometry. *Psychiatry and Clinical Neurosciences Psychiatry Clin Neurosci*, 66(7):611-7, 2012.12
5. Kinoshita M, Numata S, Tajima A, Ohi K, **Hashimoto R**, Shimodera S, Imoto I, Itakura M, Takeda M, Ohmori T. Meta-analysis of association studies between DISC1 missense variants and schizophrenia in Japanese population. *Schizophr Res*, 141(2-3):271-3, 2012.11
 6. Okada T, **Hashimoto R**, Yamamori H, Umeda-Yano S, Yasuda Y, Ohi K, Fukumoto M, Ikemoto K, KUnii Y, Tomita H, Ito A, Takeda M. Expression analysis of a novel mRNA variant of the schizophrenia risk gene ZNF804A. *Schizophr Res*, 141(2-3):277-8, 2012.11
 7. Kitazawa M, Ohnuma T, Takebayashi Y, Shibata N, Baba H, Ohi K, Yasuda Y, Nakamura Y, Aleksic B, Yoshimi A, Okochi T, Ikeda M, Naitoh H, **Hashimoto R**, Iwata N, Ozaki N, Takeda M. No Associations Found between the Genes Situated at 6p22.1, HIST1H2BJ, PRSS16 and PGBD1 in Japanese Patients Diagnosed With Schizophrenia. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, 159B(4): 456-64, 2012.6
 8. Ohi K, **Hashimoto R**, Yasuda Y, Fukumoto M, Yamamori H, Umeda-Yano S, Okada T, Kamino K, Morihara T, Iwase M, Kazui H, Numata S, Ikeda M, Ohmura T, Iwata N, Ueno S, Ozaki N, Ohmori T, Arai H, Takeda M. Functional genetic variation at the NRGN gene and schizophrenia: evidence from a gene-based case-control study and gene expression analysis. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, 159B(4):405-13, 2012.6
 9. Wallwork RS, Fortgang R, **Hashimoto R**, Weinberger DR, Dickinson D. Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. *Schizophr Res*, 137(1-3):246-50, 2012.5
 10. Watanabe Y, Egawa J, Iijima Y, Nunokawa A, Kaneko N, Shibuya M, Arinami T, Ujike H, Inada T, Iwata N, Tochigi M, Kunugi H, Itokawa Ma, Ozaki N, **Hashimoto R**, Someya T. A two-stage case-control association study between the tryptophan hydroxylase 2 (TPH2) gene and schizophrenia in a Japanese population. *Schizophrenia Research*, 137:264-266, 2012.5
 11. Koide T, Banno M, Aleksic B, Yamashita S, Kikuchi T, Kohmura K, Adachi Y, Kawano N, Kushima I, Nakamura Y, Okada T, Ikeda M, Ohi K, Yasuda Y, **Hashimoto R**, Inada T, Ujike H, Iidaka T, Suzuki M, Takeda M, Iwata N, Ozaki N. Common Variants in MAG12 Gene Are Associated with Increased Risk for Cognitive Impairment in Schizophrenic Patients. *PLoS One*, 7(5):e36836, 2012.5
 12. Kushima I, Nakamura Y, Aleksic B, Ikeda M, Ito Y, Shiino T, Okochi T, Fukuo Y, Ujike H, Suzuki M, Inada T, **Hashimoto R**, Takeda M, Kaibuchi K, Iwata N, Ozaki N. Resequencing and Association Analysis of the KALRN and EPHB1 Genes And Their Contribution to Schizophrenia Susceptibility. *Schizophr Bull*, 38(3):552-560, 2012.5
 13. Ohi K, **Hashimoto R**, Nakazawa T, Okada T, Yasuda Y, Yamamori H, Fukumoto M, Umeda-Yano S, Iwase M, Kazui H, Yamamoto T, Kano M, Takeda M. The p250GAP Gene is Associated with Risk for Schizophrenia and Schizotypal Personality Traits. *PLoS One*, 7(4):e35696, 2012.4
 14. Ohi K, **Hashimoto R**, Yasuda Y, Fukumoto M, Yamamori H, Iwase M, Kazui H, Takeda M. Personality traits and schizophrenia: evidence from a case-control study and meta-analysis.